Drugs / desferoxamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00069862 | Sep 2003 → Nov 2005 | beta thalassemia | Genzyme, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | desferoxamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00069862 ↗ |
| Known as | DFO | “desferoxamine (DFO)” NCT00069862 ↗ |